BJMO - volume 14, issue 6, october 2020
M-P. Graas MD, N. Blétard MD, M. Bourhaba , C. Focan MD, PhD
In this article the authors reviewed literature regarding mucinous ovarian carcinoma (MOC), which represents a special challenge as a rare ovarian tumour (about 3%) with unique clinical characteristics as compared to serous ovarian carcinoma (SOC). MOC is mostly diagnosed at an early stage and is generally associated with an excellent prognosis. However, later stages usually remain resistant to medical treatment, with early deaths occurring. Overall, advanced MOC patients seem 2.3 times more likely to die of their tumour as compared to SOC patients. Anatomo-pathological diagnosis and distinguishing between primary and metastasised MOC remains difficult and sometimes inconclusive, despite the contribution of immunohistochemistry (IHC) and/or molecular biology. The preservation of fertility is currently conceivable in younger patients with an early stage disease.
(BELG J MED ONCOL 2020;14(6):246-53)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
